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Abstract
Chronic periodontitis (ChP) is a prevalent inflammatory disease affecting 46% of the US population. ChP produces a profound local
inflammatory response to dysbiotic oral microbiota that leads to destruction of alveolar bone and tooth loss. ChP is also associated
with systemic illnesses, including cardiovascular diseases, malignancies, and adverse pregnancy outcomes. However, the mechanisms
underlying these adverse health outcomes are poorly understood. In this prospective cohort study, we used a highly multiplex mass
cytometry immunoassay to perform an in-depth analysis of the systemic consequences of ChP in patients before (n = 28) and after
(n = 16) periodontal treatment. A high-dimensional analysis of intracellular signaling networks revealed immune system–wide dysfunctions
differentiating patients with ChP from healthy controls. Notably, we observed exaggerated proinflammatory responses to Porphyromonas
gingivalis–derived lipopolysaccharide in circulating neutrophils and monocytes from patients with ChP. Simultaneously, natural killer
cell responses to inflammatory cytokines were attenuated. Importantly, the immune alterations associated with ChP were no longer
detectable 3 wk after periodontal treatment. Our findings demarcate systemic and cell-specific immune dysfunctions in patients with
ChP, which can be temporarily reversed by the local treatment of ChP. Future studies in larger cohorts are needed to test the
boundaries of generalizability of our results.
Keywords: mass cytometry, CyTOF, innate immunity, human, oral systemic disease, cell signaling

Introduction
Chronic periodontitis (ChP), an inflammatory disease that
affects 46% of US adults (Eke et al. 2015), is initiated by dysbiotic bacteria that activate the host’s local immune response,
thereby destroying connective tissue and bone, forming periodontal pockets, and eventually causing tooth loss. Accumulating
epidemiologic evidence also supports a strong association
between ChP and systemic diseases, including cardiovascular
disease, diabetes, Alzheimer’s disease, malignancies, and
adverse pregnancy outcomes (Bassani et al. 2007; CondeAgudelo et al. 2008; Nabet et al. 2010; Ajita et al. 2013;
Morishita et al. 2013; Nguyen et al. 2015; Peng et al. 2017).
Demonstrating a mechanistic link between ChP and adverse
health outcomes is critical for implementation of effective strategies to prevent ChP and its negative health consequences.
The standard treatment of mechanical removal of subgingival biofilm and calculus has been shown to reduce clinical
attachment loss in the short term (Smiley et al. 2015). However,
without frequent maintenance, ChP relapses, and disease progression continues, even with antimicrobial adjuncts (Becker
et al. 1984). Novel therapeutic approaches are critically needed
to prevent systemic progression of ChP. As such, therapeutic
strategies targeting peripheral inflammatory mechanisms

implicated in ChP’s systemic manifestations will enhance
treatment. To this end, basic principles can be gained from
other fields, such as cardiovascular or cancer immunotherapies,
which have demonstrated the importance of patient selection based
on individual molecular and cellular characteristics (Hamilton
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Figure 1. Experimental workflow and analytic approach. (A) Peripheral blood samples from 14 patients and 14 matched healthy controls were
collected at baseline, with a subset of 16 patients (9 patients and 7 controls) undergoing standard nonsurgical treatment for chronic periodontitis (ChP)
and an additional blood draw 3 wk after treatment. (B) Whole blood samples were either unstimulated or stimulated with receptor-specific ligands,
including lipopolysaccharide isolated from Porphyromonas gingivalis (pgLPS), interferon α (IFN-α), tumor necrosis factor α (TNF-α), and a cytokine
cocktail consisting of interleukin 2 (IL-2), IL-4, and IL-6, and granulocyte-macrophage colony-stimulating factor (GM-CSF). Samples were processed
for mass cytometry (CyTOF) analysis. (C) A cell signaling elastic net analysis of the mass cytometry data set formed a correlation network of immune
features highlighting coordinated intracellular signaling responses associated with ChP. The nodes are colored according to the stimulation condition as
indicated.

et al. 2017; Ridker, Everett, et al. 2017; Ridker, MacFadyen,
et al. 2017). To identify targetable immune mechanisms, local
and systemic functional immune characteristics need to be
mapped comprehensively across variations in ChP severity, as
well as across individuals with similar disease stages.
Current periodontal research has primarily focused on local
inflammatory mechanisms driving the destruction of alveolar
bone (Abe et al. 2012; Hajishengallis 2014). In contrast, the
systemic immunologic manifestations of ChP remain poorly
understood. Seminal studies have provided important insight
into the effect of ChP on circulating inflammatory (Ling et al.
2015) and proresolving (Van Dyke and Serhan 2003; Serhan
2014) mediators and the distribution of select immune cell subsets (Wilensky et al. 2015). However, technological limitations
have precluded the simultaneous assessment of phenotypic and
functional attributes across many immune cell subsets in
patients with ChP. Therefore, analyses reflecting the complex
behaviors of immune cells occurring in a multicellular in vivo
environment are warranted to capture the systemic immunologic imprint of ChP.
The recent advent of mass cytometry, a high-dimensional
flow cytometry platform that allows quantification of >50 proteomic parameters on a single-cell basis (Bendall et al. 2011;
Spitzer and Nolan 2016), offers unparalleled capacity for
single-cell profiling of immune mechanisms associated with
disease pathogenesis (Bendall et al. 2011; Gaudillière et al.
2014; Spitzer and Nolan 2016; Aghaeepour, Kin, et al. 2017;
Aghaeepour et al. 2018; Good et al. 2018). Here, we employed
a high-dimensional mass cytometry immunoassay and a
machine learning method developed for analysis of multicellular immune signaling networks (Aghaeepour, Ganio, et al.
2017) to characterize major innate and adaptive immune
responses in peripheral blood from patients with and without
ChP. The goals were to determine whether the peripheral
immunologic state of patients with ChP differs from that of
healthy individuals, to identify the cellular components of an
immunologic signature of ChP, and to determine whether

standard nonsurgical periodontal treatment modifies the
peripheral immunologic signature of ChP.

Materials and Methods
Study Design
This prospective study was conducted at Stanford University
and the Bell Dental Center (San Leandro, CA) after approval
by Stanford’s Institutional Review Board. Individuals aged
>18 y with stage III-IV, grade B-C periodontitis (Tonetti et al.
2018) were eligible as patients. Exclusion criteria included
immune-modulatory therapy, chemotherapy, radiation therapy,
metastatic disease, active extraoral infection, antibiotics, metabolic disease, significant organ dysfunction, substance abuse,
and smoking within the past 6 mo. Healthy adult individuals
without ChP (clinical attachment loss <1 mm, no bleeding on
probing) were eligible as controls. All participants signed written informed consent. Complete periodontal examination was
performed (pocket depths at 6 sites per tooth with a Marquis
color-coded probe, recession, bleeding on probing, mobility).
Hard tissue examination and radiographs were also performed,
with caries, periapical abscesses, and radiographic calculus
recorded. This study conformed with STROBE guidelines for
human observational studies.
Sixteen participants were available for a return visit, including 7 controls and 9 patients with ChP. These patients underwent full-mouth disinfection treatment (Fang et al. 2016)
consisting of scaling and root planing for patients with ChP or
prophylactic cleaning for controls, followed by directed home
oral hygiene, including 0.12% chlorhexidine mouth rinse twice
daily for both study arms. A second blood draw for the treatment cohort was performed at 3 wk following this intervention
(Fig. 1A), as well as qualitative periodontal examination and
interview to determine compliance with the home hygiene regimen. In all cases, there was marked qualitative improvement of
the periodontal condition and compliance with home hygiene.
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Sample Collection and Mass Cytometry Analysis

Results

Whole-blood samples collected at baseline (n = 28) and 3 wk
after treatment (n = 16) were left unstimulated or stimulated
with Porphyromonas gingivalis lipopolysaccharide (PgLPS),
interferon α (IFNα), tumor necrosis factor α (TNFα), or a
cytokine cocktail containing interleukins 2/4/6 (IL-2/4/6) and
granulocyte-macrophage colony-stimulating factor (GM-CSF;
Fig. 1A). Stimulation conditions were chosen to evaluate the
integrity of intracellular signaling pathways activated downstream of key inflammatory mediators implicated in the pathogenesis of ChP (Appendix Methods). Samples were processed
for mass cytometry with standardized protocols (Appendix
Methods). The mass cytometry data were manually gated into
18 immune cell subsets representing major innate and adaptive
compartments (Appendix Table 2).
Three categories of immune features were obtained:

Single-Cell Profiling of Peripheral Immune Status
in Patients with ChP

Cell frequency: Cell counts were expressed as a percentage
of leukocytes for neutrophils (Nφ’s) and mononuclear
cells for other cell types.
Endogenous signaling immune features: Endogenous intracellular signaling activities—arcsinh transform of the
signal for phospho (p)P38, pMAPKAPK2, prpS6, pNFκB, pCREB, pERK1/2, pSTAT1, pSTAT3, pSTAT5,
pSTAT6, and total IκB—reflective of canonical signaling pathways implicated in ChP were quantified with
unstimulated samples.
Evoked intracellular signaling features: Signaling responses
(arcsinh ratio of the intracellular signal intensity between
the stimulated and unstimulated conditions) were analyzed in samples stimulated with PgLPS, IFNα, TNFα,
or IL-2/4/6 with GM-CSF. The transformed ratios were
z scored for further analysis.

Thirty participants were enrolled in the study, including 15
with ChP receiving treatment and 15 sex- and age-matched
healthy volunteers. One patient was excluded due to onset of
treatment for autoimmune disease, and 1 control was excluded
due to a hand infection. Demographics and comorbidities for
all participants and the periodontal status of patients with ChP
are listed in the Table. Nine patients and 7 controls were available to follow up 3 wk after scaling and root planing or prophylaxis as appropriate (Fig. 1A).

Analysis of Immune Signaling Networks
Identifies a Peripheral Immune Signature of ChP
The high-dimensional mass cytometry data set formed a correlation network emphasizing the interconnectivity of measured immune features (Fig. 1B, C). The highly intercorrelated
nature of the data justified the use of the csEN regularized
regression algorithm (Aghaeepour, Ganio, et al. 2017). The
csEN analysis identified a statistically stringent linear model
that differentiated patients with ChP from controls according to
their evoked signaling response to PgLPS, IFNα, TNFα, or
IL-2/4/6 with GM-CSF stimulation (cross-validation P value =
1.673E-4; Fig. 2). Coefficients of the csEN model were visualized on the correlation network (Fig. 2B). Individual features
selected by the model are listed in Appendix Table 3.
Interestingly, no differences in immune cell frequencies were
detected between patients with ChP and controls, suggesting
that the functional attributes are more informative than the
assessment of cell distribution in the immunologic profile of
patients with ChP.

Graphical Representation
Pairwise Spearman rank correlation analysis was performed on
all immune features. Edges in the correlation network graphs
represent a significant correlation (P < 5.0E-5) between 2
immune features. The layout was constructed with the t-SNE
algorithm (Maaten and Hinton 2008).

Statistical Analysis
Statistical analysis of the mass cytometry data was performed
with the cell signaling elastic net (csEN) method (Aghaeepour,
Ganio, et al. 2017), a recent adaptation of the penalized linear
regression elastic net (Zou and Hastie 2005), which considers
previous biological knowledge of cell type– and receptorspecific signaling pathway activation. csEN models were optimized and trained via cross-validation, and a repeat hold-out
approach was used to test for statistical significance. To aid the
biological interpretation of the csEN model, individual model
components were ranked according to the strength of the association with ChP (–log[P value], Wilcoxon rank sum test;
details in Appendix Methods).

ChP Is Associated with Profound and Cell-Specific
Peripheral Immune Dysfunctions
To further evaluate the biological implications of the results,
features included in the csEN model were examined individually. Model components were ranked according to the strength
of their association with ChP (–log[P value], Wilcoxon rank
sum test). Examination of the model components that differed
the most between patients with ChP and controls pointed at
specific biological mechanisms differentially regulated in ChP,
which provided the basis for the biological interpretation of the
statistical model. Of the 37 csEN features that differed between
patients with ChP and controls, the majority were signaling
responses to the cytokine cocktail (40%) and PgLPS stimulations (35%). Innate immune cell signaling responses accounted
for 76% of the features, while 34% were signaling responses in
adaptive cells (Appendix Table 3).
Seventeen model features were canonical elements of
known signaling pathways activated in response to the specific
stimulation (Appendix Table 4), while 20 features were
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Table. Demographic and Clinical Data.

Age, y, median (range)
Sex, n
Male
Female
Race/ethnicity, n (%)
African American
Asian
Caucasian
Latino
Body mass index, mean (range)
Comorbidities, n
Anemia
Hypertension
Morphea
Thyroid disease
Periodontal classification, n
Stage III
Stage IV
Deepest periodontal pocket, mm, mean (SD)
Largest clinical attachment loss, mm, mean (SD)
No. of pockets ≥5 mm, median (range)
No. of teeth with furcation involvement, median (range)
No. of sites with radiographic calculus, median (range)

Patients with ChP (n = 14)

Healthy Controls (n = 14)

P Value

40.5 (29 to 61)

36.5 (26 to 57)

0.12a
>0.99b

6
8

6
8

2 (14)
3 (21)
0 (0)
9 (64)
28.9 (19 to 40)

2 (14)
6 (43)
3 (21)
3 (21)
24.6 (19 to 31)

1
1
0
1

0
0
1
0

0.072b

0.07a

10
4
7.60 (1.12)
8.42 (1.73)
36 (7 to 84)
0 (0 to 2)
8 (2 to 27)

ChP, chronic periodontitis.
a
T test.
b
Chi-square.

Figure 2. A cell signaling–based elastic net (csEN) analysis identifies systemic immune signaling features associated with chronic periodontitis (ChP).
(A) We adapted a previously implemented cell signaling–based penalization matrix for the csEN analysis that accounted for whether a cell type– and
receptor-specific signaling response to each stimulation condition is supported by prior knowledge of signal transduction pathways. (B) (Left panel) The
csEN identified immune signaling features that differentiate samples from patients with ChP and those from controls at baseline. Each node is colored
by model coefficient. Red and blue indicate features elevated and decreased in samples from patients at baseline, respectively. Node size is proportional
to the P value of the difference between patient and control samples (Wilcoxon rank sum test). (Right panel) For each of the 28 patients, a unique
model value from the csEN is represented as a z score in the box plot showing that the model significantly differentiates the patients with ChP (n = 14)
from the controls (n = 14). Values are presented as median, interquartile range, and range.

noncanonical signaling responses. Six canonical csEN model
features were signaling responses to PgLPS in various innate
immune cell subsets and included pCREB, pNF-κB, and pERK

signaling responses in classical (c)MCs, pNF-κB signaling
response in Nφs, pCREB signaling response in myeloid dendritic cells, and pERK signaling response in monocytic
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Figure 3. The cell signaling–based elastic net (csEN) model reveals systemic immune alterations associated with chronic periodontitis (ChP). (Center)
Baseline immune network with the 17 canonical features selected by the csEN model, labeled on the correlation network, that differ between patients
with ChP and controls. (Periphery) Box plots depicting 12 canonical csEN model components (arcsinh ratio of the stimulated samples as compared with
unstimulated samples, z scored). Values are presented as median, interquartile range, and range. Additional model components are listed in Appendix
Table 3. GM-CSF, granulocyte-macrophage colony-stimulating factor; LPS, lipopolysaccharide; TNFα, tumor necrosis factor α.

myeloid-derived suppressor cells. These signaling responses to
PgLPS were all increased in patients with ChP as compared
with controls, suggesting that ChP is associated with heightened TLR-2/4 signaling in peripheral innate immune cells.
In contrast to PgLPS signaling responses, csEN model features representing signaling responses to TNFa, IFNa, or
IL-2/4/6 and GM-CSF stimulations were suppressed in patients
with ChP as compared with controls (Fig. 3). These csEN features included the pMAPKAPK2 signaling response to TNFa
and the pSTAT1, pSTAT3, and pERK signaling response to
IL-2/4/6 and GM-CSF in NK cells subsets; the pSTAT1 signaling response to IL-2/4/6 and GM-CSF in intermediate (int)
MCs; and the pCREB signaling response to TNFa in B cells,
representing broad immunosuppression.
These results suggest that the capacity of specific immune
cell subsets to respond to an inflammatory challenge is altered
in peripheral blood samples from patients with ChP. The most
prominent differences between the immune features of the 2
study arms were observed in innate immune cells and included

heightened TLR-2/4 responses to PgLPS and depressed signaling responses to TNFa, IFNa, and IL-2/4/6 and GM-CSF.
Features identified by the csEN model were not significantly
associated with the sex (independent samples t test), race
(1-way analysis of variance), body mass index, or age
(Pearson’s correlation; Bonferroni-corrected a = 0.0014) of the
patient.
To determine whether observed differences in immune
responses between patients with ChP and controls resulted
from the local dysbiosis of the oral cavity, rather than from
variables that could not be captured in the study design,
immune responses were again examined 3 wk after nonsurgical ChP treatment (n = 9) or prophylaxis (n = 7).

Immune Signature Associated with ChP Resolves
after ChP Treatment
The csEN model trained on the immunologic data set derived
from 28 patients at baseline was applied to the data set obtained
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Figure 4. Chronic periodontitis (ChP) treatment reverses aspects of the systemic immune manifestations of ChP. (A) Box plot depicting the cell
signaling–based elastic net (csEN) model values in samples from patients with ChP and controls in the treatment cohort, before and after ChP
treatment. The csEN values are increased in samples from patients with ChP before treatment as compared with controls (9 patients, 7 controls,
Wilcoxon rank sum test P = 7.9E-3) but not after treatment. Values are presented as median, interquartile range, and range. (B, C) csEN model
component values overlaid on the immune signaling network for the patients who underwent scaling and root planing (n = 9) or prophylactic cleaning
(n = 7). Nodes are colored by the median difference in signaling activity (arcsinh transform) between patients with ChP and controls. The size of the
nodes varies according to the P value (Wilcoxon rank sum test, 1-tailed). (B) Before treatment. (C) After treatment.

from the analysis of blood samples collected from the 16
patients who underwent ChP treatment. This analysis provided
a predicted value per study participant before and after ChP
treatment. The data showed that the csEN predictions significantly separated the cohort of patients with ChP from the controls (P = 7.9E-3; Fig. 4A, B) at baseline but not after ChP
treatment (Fig. 4C). These results suggest that the systemic
immune signature of ChP identified in this study is driven, at
least in part, by local pathologic processes that are sensitive to
disinfection of the oral cavity.

Discussion
This study employed a multiplex mass cytometry assay to provide an in-depth survey of the systemic immunologic manifestations of ChP in patients, before and 3 wk after periodontal

treatment. High-dimensional analysis of immune signaling
networks identified a statistically stringent model of peripheral
immune responses that accurately classified patients’ periodontal status. These findings demarcate a peripheral immune
signature that specifies the systemic inflammatory state of
patients with ChP.
The systemic consequences of ChP rely on the integration
of numerous interconnected immunologic events. The ability
to simultaneously quantify these immunologic events with
single-cell resolution has been possible with only the recent
development of high-parameter, single-cell technologies such
as mass cytometry (Bendall et al. 2011). However, the large
immunologic data set derived from the mass cytometry analysis of clinical samples presents several computational challenges (James et al. 2013). First, the number of measured
immune features often greatly outnumbers the sample size,
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which leads to false-positive discoveries (Tibshirani 1996;
Newell and Cheng 2016). Second, the nature of mass cytometry data is highly correlated, reflecting the coordinated interactions between immune cells (Zou and Hastie 2005). Both of
these challenges are addressed with the csEN analysis, which
was recently shown to outperform other common machine
learning methods in the analysis of mass cytometry data sets
(Aghaeepour, Ganio, et al. 2017).
The longitudinal profile of peripheral immune responses
before and after ChP treatment revealed the remarkable plasticity of the peripheral immune system in patients with ChP.
Globally, the integrated output of all measured immune
responses captured by the csEN analysis strongly differentiated patients with ChP from controls at baseline. However, differences in csEN model values between controls and patients
were markedly decreased 3 wk after ChP treatment. These
results suggest that the immunologic differences observed
before treatment are attributable to ChP rather than to unaccounted clinical or demographic variables. The findings also
point to the ability of the peripheral immune system of patients
with ChP to evolve from a dysfunctional to a relatively normal
state after a 3-wk intervention targeting the local manifestations of ChP (Smiley et al. 2015). Interestingly, there was a
trend toward a relative decrease in csEN model predictions for
patients with ChP as compared with controls after treatment.
This may reflect the fact that the patient’s immune system has
not fully adjusted 3 wk after treatment. As such, the 3-wk posttreatment time point provides only a snapshot of the patient’s
immune system adjustment after treatment.
In addition, high interpatient variability existed among
immune responses. This variability may reflect patient-specific
immunologic states underlying individual differences in periodontal pathogen communities or varying degrees of periodontitis. These findings are reminiscent of prior omics
characterizations of systemic inflammatory states, such as
aging and cancer, showing genetic, metabolic, and immune
variability within a predefined clinical class that predicts
adverse clinical outcomes or response to therapy (Gaudillière
et al. 2014; Aghaeepour, Kin, et al. 2017; Good et al. 2018).
The most informative features of the ChP immune signature
included increased elements of the TLR-2/4 signaling
responses to PgLPS, 1 of 4 major virulence factors of Pg
(Johansson and Dahlen 2018), in multiple innate immune cell
types. These results resonate with previous reports showing an
exacerbation of Nϕ activation in local gingival tissues and in
peripheral blood from patients with ChP (Hajishengallis 2015).
For example, Ling et al. (2015) observed an increase in proinflammatory Pg-related cytokines IL-8 and IL-1β from peripheral Nϕs in patients with ChP as compared with controls.
Furthermore, in a bovine study, TLR-2/4 gene expression was
upregulated in periodontal tissues of animals with periodontitis
(Borsanelli et al. 2018). The increased signaling responses to
PgLPS suggests a priming effect of ChP on peripheral innate
immune cells, perhaps through upregulation of the TLR-2/4
receptors. Whether the priming of peripheral innate immune
cells to subsequent PgLPS exposure results from a chronic
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exposure to circulating periodontal pathogens or indirectly from
the chronic release of proinflammatory cytokines, such as TNFα
and IL-1β, from periodontal tissue remains to be determined.
Other findings are unexpected. For example, in contrast to
enhanced innate responses to PgLPS, a dampening of signaling responses to GM-CSF and proinflammatory cytokines
TNFα and IL-2/4/6 was observed in NK cells, intMCs, and B
cells. Interestingly, the decreased pMAPKAPK2 seen in the
CD56loCD16+ NK cell subset was related to the severity of
ChP, with patients with stage IV ChP having a greater degree
of suppression than those with stage III ChP (Appendix Table
5). Previous studies of NK cells have predominantly focused
on local mechanisms and suggest that NK cell activity promotes periodontal destruction. In mice, periodontal pathogens
can activate NK cells to secrete IFNγ and TNFa, leading to
fibroblast and osteoclast stimulation and subsequent degradation of extracellular matrix and alveolar bone (Wilensky et al.
2015). These studies also point to the expansion of NK cells in
the local periodontal tissues (Górska et al. 2003). Our findings
of decreased peripheral NK cell function in patients with ChP
suggest that circulating NK cell responses may not reflect local
NK cell function. In contrast, the relative NK cell anergy
observed in the peripheral blood of patients with ChP may be
implicated in the pathogenesis of systemic illnesses that are
linked to periodontitis, such as systemic infections (endocarditis, pneumonia) and malignancies (Lorini et al. 1994).
This study has certain limitations. The small sample size of
patients recruited from a single clinic may not represent the
entire population or the entire spectrum of the disease, limiting
the generalizability of the results. Larger studies from multiple
sites will be required for validation of these findings. As all
comorbidities and potential confounders cannot be eliminated—such as clinical or demographic variables potentially
associated with ChP that were not captured in the study design,
including nutrition, socioeconomic status, or undiagnosed illness—a study linking local pathology from gingival tissue and
the peripheral immune response will be critical to better understand systemic dysfunction. In addition, as the periodontal status tends to relapse without frequent oral maintenance therapy,
we would expect the immune signature of ChP to recur over a
period of several weeks to months, which is not captured in the
present study, with only a 3-wk follow-up. This expected
relapse of the peripheral immune dysfunction justifies the
development of adjunct therapies that complement standard
periodontal treatment. While the mass cytometry assay allows
measurement of >40 parameters per cell, the list of phenotypic
markers and signaling responses tested is not exhaustive, nor is
the stimulation panel. Similarly, the analysis was performed on
manually gated populations to allow application of the csEN
method. As such, we cannot exclude that additional features
would have been detected with an unbiased clustering
approach. However, the approach provides the analytic framework to expand the immunoassay to allow assessment of all
immune cell dysfunctions associated with ChP and provide the
basis for future multiomics research (Ghaemi et al. 2018) on
ChP.
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The data-driven development of cell- and pathway-specific immune therapies represents a paradigm shift in the
treatment of ChP and the prevention of associated systemic
illnesses (Tonetti et al. 2011). As an essential step toward this
goal, our study revealed systemic immune cell dysfunctions
associated with ChP that were reversible after treatment,
highlighting a peripheral immune signature of ChP. These
findings and analytic approach provide the framework for
future efforts toward testing the boundaries of generalizability of our results and identifying modifiable targets for the
development of novel therapies to prevent the systemic consequences of ChP.
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